Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancer

Kimio Yonesaka, Taroh Satoh, Shinya Ueda, Takeshi Yoshida, Masayuki Takeda, Toshio Shimizu, Isamu Okamoto, Kazuto Nishio, Takao Tamura, Kazuhiko Nakagawa

研究成果: ジャーナルへの寄稿記事

9 引用 (Scopus)

抄録

Background/Aim: The epidermal growth factor family (EGF) has been suggested to influence the sensitivity to anti-epidermal growth factor receptor therapy. We examined the correlation between circulating levels of the epidermal growth factors amphiregulin and transforming growth factor-α (TGF-α) and the MET ligand hepatocyte growth factor and sensitivity to the anti-epidermal growth factor receptor antibody in colorectal cancer (CRC) patients. Materials and Methods: Plasma levels of each ligand were measured by enzyme-linked immunosorbent assay in 51 patients with wild-type KRAS CRC. Results: Patients with high hepatocyte growth factor (HGF) levels had a significantly lower disease control rate (DCR) and shorter median progression-free survival (PFS) and overall survival (OS) than those with low expression levels. Amphiregulin was correlated with objective response rate (ORR) but not with PFS or OS. Cetuximab response and survival were not associated with TGF-α. Conclusion: Circulating HGF may help identify CRC patients most likely to benefit from antiepidermal growth factor receptor antibody therapy.

元の言語英語
ページ(範囲)1683-1690
ページ数8
ジャーナルAnticancer Research
35
発行部数3
出版物ステータス出版済み - 3 1 2015

Fingerprint

Hepatocyte Growth Factor
Colorectal Neoplasms
Transforming Growth Factors
Epidermal Growth Factor Receptor
Disease-Free Survival
Survival
Ligands
Growth Factor Receptors
Antibodies
Epidermal Growth Factor
Enzyme-Linked Immunosorbent Assay
Cetuximab
Therapeutics
Amphiregulin

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Yonesaka, K., Satoh, T., Ueda, S., Yoshida, T., Takeda, M., Shimizu, T., ... Nakagawa, K. (2015). Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancer. Anticancer Research, 35(3), 1683-1690.

Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancer. / Yonesaka, Kimio; Satoh, Taroh; Ueda, Shinya; Yoshida, Takeshi; Takeda, Masayuki; Shimizu, Toshio; Okamoto, Isamu; Nishio, Kazuto; Tamura, Takao; Nakagawa, Kazuhiko.

:: Anticancer Research, 巻 35, 番号 3, 01.03.2015, p. 1683-1690.

研究成果: ジャーナルへの寄稿記事

Yonesaka, K, Satoh, T, Ueda, S, Yoshida, T, Takeda, M, Shimizu, T, Okamoto, I, Nishio, K, Tamura, T & Nakagawa, K 2015, 'Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancer', Anticancer Research, 巻. 35, 番号 3, pp. 1683-1690.
Yonesaka K, Satoh T, Ueda S, Yoshida T, Takeda M, Shimizu T その他. Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancer. Anticancer Research. 2015 3 1;35(3):1683-1690.
Yonesaka, Kimio ; Satoh, Taroh ; Ueda, Shinya ; Yoshida, Takeshi ; Takeda, Masayuki ; Shimizu, Toshio ; Okamoto, Isamu ; Nishio, Kazuto ; Tamura, Takao ; Nakagawa, Kazuhiko. / Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancer. :: Anticancer Research. 2015 ; 巻 35, 番号 3. pp. 1683-1690.
@article{0984959d618b44abae4a507f1f07fb74,
title = "Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancer",
abstract = "Background/Aim: The epidermal growth factor family (EGF) has been suggested to influence the sensitivity to anti-epidermal growth factor receptor therapy. We examined the correlation between circulating levels of the epidermal growth factors amphiregulin and transforming growth factor-α (TGF-α) and the MET ligand hepatocyte growth factor and sensitivity to the anti-epidermal growth factor receptor antibody in colorectal cancer (CRC) patients. Materials and Methods: Plasma levels of each ligand were measured by enzyme-linked immunosorbent assay in 51 patients with wild-type KRAS CRC. Results: Patients with high hepatocyte growth factor (HGF) levels had a significantly lower disease control rate (DCR) and shorter median progression-free survival (PFS) and overall survival (OS) than those with low expression levels. Amphiregulin was correlated with objective response rate (ORR) but not with PFS or OS. Cetuximab response and survival were not associated with TGF-α. Conclusion: Circulating HGF may help identify CRC patients most likely to benefit from antiepidermal growth factor receptor antibody therapy.",
author = "Kimio Yonesaka and Taroh Satoh and Shinya Ueda and Takeshi Yoshida and Masayuki Takeda and Toshio Shimizu and Isamu Okamoto and Kazuto Nishio and Takao Tamura and Kazuhiko Nakagawa",
year = "2015",
month = "3",
day = "1",
language = "English",
volume = "35",
pages = "1683--1690",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3",

}

TY - JOUR

T1 - Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancer

AU - Yonesaka, Kimio

AU - Satoh, Taroh

AU - Ueda, Shinya

AU - Yoshida, Takeshi

AU - Takeda, Masayuki

AU - Shimizu, Toshio

AU - Okamoto, Isamu

AU - Nishio, Kazuto

AU - Tamura, Takao

AU - Nakagawa, Kazuhiko

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Background/Aim: The epidermal growth factor family (EGF) has been suggested to influence the sensitivity to anti-epidermal growth factor receptor therapy. We examined the correlation between circulating levels of the epidermal growth factors amphiregulin and transforming growth factor-α (TGF-α) and the MET ligand hepatocyte growth factor and sensitivity to the anti-epidermal growth factor receptor antibody in colorectal cancer (CRC) patients. Materials and Methods: Plasma levels of each ligand were measured by enzyme-linked immunosorbent assay in 51 patients with wild-type KRAS CRC. Results: Patients with high hepatocyte growth factor (HGF) levels had a significantly lower disease control rate (DCR) and shorter median progression-free survival (PFS) and overall survival (OS) than those with low expression levels. Amphiregulin was correlated with objective response rate (ORR) but not with PFS or OS. Cetuximab response and survival were not associated with TGF-α. Conclusion: Circulating HGF may help identify CRC patients most likely to benefit from antiepidermal growth factor receptor antibody therapy.

AB - Background/Aim: The epidermal growth factor family (EGF) has been suggested to influence the sensitivity to anti-epidermal growth factor receptor therapy. We examined the correlation between circulating levels of the epidermal growth factors amphiregulin and transforming growth factor-α (TGF-α) and the MET ligand hepatocyte growth factor and sensitivity to the anti-epidermal growth factor receptor antibody in colorectal cancer (CRC) patients. Materials and Methods: Plasma levels of each ligand were measured by enzyme-linked immunosorbent assay in 51 patients with wild-type KRAS CRC. Results: Patients with high hepatocyte growth factor (HGF) levels had a significantly lower disease control rate (DCR) and shorter median progression-free survival (PFS) and overall survival (OS) than those with low expression levels. Amphiregulin was correlated with objective response rate (ORR) but not with PFS or OS. Cetuximab response and survival were not associated with TGF-α. Conclusion: Circulating HGF may help identify CRC patients most likely to benefit from antiepidermal growth factor receptor antibody therapy.

UR - http://www.scopus.com/inward/record.url?scp=84924937221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924937221&partnerID=8YFLogxK

M3 - Article

C2 - 25750328

AN - SCOPUS:84924937221

VL - 35

SP - 1683

EP - 1690

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3

ER -